Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normothermic intraperitoneal oxaliplatin after CRS and HIPEC in colorectal cancer peritoneal metastases (NIPEC-OXA)
2020-004944-27Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by Oslo University Hospital. Primary endpoint: Adverse events by CTCAE v5.0. Started Nov 2020; status: active.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-004944-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004944-27.